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A Focus on Unusual ECL2 Interactions Yields β2-Adrenergic
Receptor Antagonists with Unprecedented Scaffolds
Magdalena M. Scharf+,[a] Mirjam Zimmermann+,[b] Florian Wilhelm,[b, c] Raimond Stroe,[b, d]
Maria Waldhoer,*[b] and Peter Kolb*[a]
The binding pockets of aminergic G protein-coupled receptors
are often targeted by drugs and virtual screening campaigns. In
order to find ligands with unprecedented scaffolds for one of
the best-investigated receptors of this subfamily, the β2-
adrenergic receptor, we conducted a docking-based screen
insisting that molecules would address previously untargeted
residues in extracellular loop 2. We here report the discovery of
ligands with a previously undescribed coumaran-based scaffold.
Furthermore, we provide an analysis of the added value that X-
ray structures in different conformations deliver for such
docking screens.
Introduction
G protein-coupled receptors (GPCRs) are involved in a plethora
of physiological and pathophysiological processes in the human
body and are targeted by approximately one third of currently
marketed drugs.[1,2] One of the best-studied members of this
large protein family is the β2-adrenergic receptor (B2AR), a class
A aminergic receptor that regulates smooth muscle relaxation
and cardiovascular events, amongst others. Several agonists of
this receptor are in clinical use as asthma medication. Antago-
nists of the B2AR (=beta-blockers) have widely been used in
the treatment of cardiovascular diseases (for a review see[3]).
Recently, the beta-blocker propranolol has been reported to be
effective in the treatment of infantile hemangioma.[4] However,
concerns about the effects of propranolol on the central
nervous system (CNS) in infantile hemangioma patients have
been raised.[5] Hence the quest for safer drug candidates acting
at the B2AR is ongoing, despite its history of more than seven
decades as a drug target. Here, we set out to identify novel
chemical entities (NCEs) using computational docking and
focusing on ligand-receptor interactions that have so far not
been exploited by many ligands. The activity of all compounds
was verified in vitro. As we were docking to a structure of the
B2AR in an inactive conformation (PDB ID: 3NY9), the expect-
ation was that we would predominantly find antagonists and
inverse agonists, that is, beta-blockers.[6,7]
In the wake of the first X-ray structure of the B2AR,[8,9]
several computational docking studies had reported NCEs for
this receptor.[6,10–12] One of the ligands emerging from this
screen targeting PDB ID 2RH1 was compound 1,[6] which was
later crystallized in complex with the B2AR. The corresponding
crystal structure (PDB ID: 3NY9[13]) with this novel nanomolar-
affinity inverse agonist showed the accuracy of the docking
prediction, demonstrated by a root-mean-square deviation
(RMSD) of only 0.9 Å.[13]
The classical pharmacophore for the B2AR, as exemplified
by adrenaline, consists of a protonatable amine that interacts
with Asp1133.32, a hydroxyl group in β-position, and an aromatic
moiety in 4–5 Å distance from the nitrogen. At the aromatic
end, ligands can interact with the serines in helix 5, but this is
neither a requirement for affinity nor agonistic efficacy.[14] At the
same time, ligands interacting with other amino acids in and
around the orthosteric binding pocket might stabilize unusual
receptor conformations and feature chemical compositions that
have not yet been described for B2AR ligands. For instance,
interaction with extracellular loop 2 (ECL2), which is in proximity
to the orthosteric binding pocket, might lead to such rarely
targeted receptor conformations.[15]
Here, we describe novel ligands with previously unreported
structural scaffolds for the B2AR resulting from the docking
calculations. These calculations were performed on two con-
formations of the receptor representing inactive states in
complex with two different inverse agonists, that is, in complex
with carazolol (PDB ID: 2RH1[8]) and in complex with compound
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1,[6] respectively. The selection of these structures was based on
the hypothesis that antagonists for the B2AR should be
enriched in docking calculations to an inactive receptor
conformation. A direct comparison of the docking using the
3NY9 structure with our previous docking study using B2AR
structure 2RH1[6] allowed us to evaluate whether such repeated
docking screens against only subtly different conformations of
the same receptor would reveal different ligand sets, as has
previously been shown for fragment screens on other GPCRs.[16]
The lead-like subset of ZINC was docked to both crystal
structures, 2RH1 and 3NY9, and molecules with novel structural
scaffolds were selected after visual inspection of their docking
poses, with an eye towards molecules that would interact with
ECL2. The selected molecules were then tested in vitro to
determine their binding affinities towards the B2AR in human
embryonic kidney cells overexpressing a SNAP-tagged version
of the B2AR (=SNAP-B2AR HEK). Although the overall hit rate
was low, we were indeed able to identify 1 (MS008) as a ligand
with an unprecedented structural scaffold. This novel scaffold
then served as a template for a subsequent similarity search.
Five additional hits with comparable affinities (with pKi values
ranging from 6.0 to 6.9) as well as six hits with lower affinities
were thus identified.
Results
The top-ranked molecule poses resulting from the docking of
the ZINC12 lead-like subset to the two crystal structures in an
inactive conformation (PDB IDs: 3NY9 and 2RH1) were eval-
uated visually. Only those molecules were selected that
contained satisfied polar interactions but no features that
remain unpunished due to the known deficiencies in present-
day scoring functions.[17] During the selection process, a special
focus was directed toward interactions with the ECL2. Based on
the interactions that were most frequently observed, the
selected molecules were grouped into three categories “no
ECL2 interaction”, “interaction with T195 in ECL2”, and “inter-
action with one of C19145.50-F19345.52 in ECL2” (numbers in
superscript according to the Ballesteros-Weinstein enumeration
scheme[18]). During selection, a particular focus was put on novel
structural scaffolds of the potential ligands, different from the
well-known β-hydroxyamine. While a variety of possible scaf-
folds was explored, all of them showed interaction with D1133.32
by either an amine or an amide in their docking pose. Following
these criteria, 27 compounds were identified, purchased from
their respective vendors, and subjected to in vitro binding
assays (Table S5 in the Supporting Information).
Heterologous competition binding assays were performed
on SNAP-B2AR HEK membranes using the fluorescent ligand
Pindolol-RED (data not shown). Out of the 27 compounds, only
one ligand, 1 (MS008), bound with measurable affinity to the
B2AR (pKi=7.0�0.1 (mean�SD, n=5)), but featured a pre-
viously undescribed coumaran-based scaffold (2,3-dihydro-1-
benzofuran-2-ylmethanamine). Such an affinity is within the
range of the clinically used ligand isoproterenol, which binds
with a pKi of 6.4.
[19–21] The molecule pose from the docking
calculations suggests that 1 (MS008) interacts with the B2AR at
the essential residues D1133.32 and N3127.39 through ionic
interactions with its primary amine. The coumaran structure is
located in the orthosteric binding pocket and stabilized by
hydrophobic interactions with V1143.33. This pose orients the
aromatic ring attached to the coumaran towards the extrac-
ellular side of the receptor, allowing for a hydrogen bond
between T195 in ECL2 and the methoxy group of the ligand
(Figure 1). Thus, the pose falls into the “T195 interaction” group.
Due to the novelty of 1 (MS008)’s scaffold and a chemical
structure that is amenable to synthetic modifications at several
positions, we decided to continue with an “analogue by
catalogue” search. Compound 1 (MS008) was used as a
template to explore a possible structure activity relationship
(SAR) between similar NCEs at the B2AR. The set of analogues
consisted of 84 molecules and was docked to the inactive
conformation structure 3NY9 as 1 (MS008) was originally picked
from the docking screen to that structure. Eleven molecules
were selected from the resulting docking poses and charac-
terized pharmacologically (Table 1). Each of the selected
molecules contained a coumaran scaffold (as 1 (MS008))
connected to a primary amine and an aromatic moiety. Eight of
the selected eleven compounds entertained the interaction
with T195 in ECL2 in their docking pose.
The novelty of the coumaran-based scaffold of compound 1
(MS008) was confirmed by comparing the ligands identified in
this study against the B2AR ligands described in ChEMBL.[22] For
each of the twelve ligands, that is, 1 (MS008) as well as the
molecules derived from it, the most similar compounds were
determined in the ChEMBL molecule set containing all mole-
cules that were active against the B2AR. The closest match that
was found was for 7 and CHEMBL1383731 with an ECFP4
Tanimoto value of 0.35 (Table S3). To cast an even wider net,
we evaluated the similarity of 1 (MS008) and its derivatives
against the set of all molecules that showed activity against any
of the adrenergic receptor subtypes in Homo sapiens. In this
search, compound 4 and CHEMBL222798 showed the highest
Figure 1. Docked pose of 1 (MS008) in the orthosteric binding pocket of the
B2AR as predicted by the docking calculation to the inactive conformation
structure 3NY9. The molecule forms hydrogen bonds with residues D1133.32,
N3127.39, and T195 in ECL2.
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similarity with an ECFP4 Tanimoto value of 0.40 (Table S4).
However, neither CHEMBL1383731 nor CHEMBL222798 feature
a coumaran scaffold.
Additionally, we conducted a substructure search on the set
of active molecules of any adrenergic receptor with three
substructures of different sizes, a) coumaran, b) the coumaran-
based scaffold (2,3-dihydro-1-benzofuran-2-ylmethanamine)
identified in this work and c) the substructure of case (b) with a
benzyl attached to the coumaran moiety. Search (a) resulted in
nine molecules, two of which are actives for the B2AR, however,
with a calculated Tanimoto similarity of 0.14–0.24 to com-
pounds 1–12. Search (b) resulted in the known α2-adrenergic
receptor ligand Efaroxan, which has a Tanimoto similarity of
only 0.16–0.19 to compounds 1–12. Search (c) did not yield any
molecules.
Table 1. Assay results of 1 (MS008) and its tested analogues in heterolo-
gous competition HTRF binding assays to the B2AR. pKi values were
determined in an equilibrium competition binding assay with 50 nM
Propranolol-green. pKi is defined as -logKi and values are shown as mean�
SD of at least three independent experiments carried out in duplicate.
Isoproterenol was used as a literature-known reference compound.
Compound Structure pKi n
1 (MS008)[a] 7.0�0.1 5
2[b] 6.9�0.1 3
3[c] 4.9�0.2 3
4 6.2�0.2 3
5 5.6�0.1 3
6 6.0�0.1 3
7 5.9�0.2 3
8 6.8�0.1 3
Table 1. continued
Compound Structure pKi n
9[c] 5.8�0.2 3
10[c] 5.0�0.3 3
11 6.1�0.1 3
12 4.6�0.1 3
Isoproterenol 6.6�0.1 4
[a] Compound from primary screen that was used for analogue search. [b]
Compound showed weak autofluorescence, but was not tested in radio-
ligand binding assay due to its similarity to 1 (MS008) and 8. [c]
Compounds showed weak autofluorescence but were not tested in radio-
ligand binding assay due to their low affinities.
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Pharmacological characterization of 1 (MS008) and its
derivatives
To characterize the binding properties of the fluorescent ligand
Propranolol-green, we performed a saturation binding experi-
ment with increasing concentrations of Propranolol-green and
2 μg SNAP-B2AR HEK membranes. Specific binding (Figure S1,
empty circles) was saturable and of high affinity with an
equilibrium dissociation constant (KD) of 48.0�7.4 nM (mean�
SD, n=1). Heterologous competition binding assays were
performed on SNAP-B2AR HEK membranes using 50 nM fluo-
rescent ligand Propranolol-green. Isoproterenol was used as a
reference molecule and its pKi of 6.6�0.1 (mean�SD, n=4) in
this assay was comparable to the values reported in literature.[21]
The parent compound 1 (MS008) showed the highest affinity
for the B2AR with a pKi value of 7.0�0.1 (mean�SD, n=5),
followed by 2 with pKi=6.9�0.1 (mean�SD, n=3) and 8 with
pKi=6.8�0.1 (mean�SD, n=3; Figure 2A, * black circles and
~ black triangles). All other ligands showed lower affinity for
the B2AR than 1 (Figure 2A, Table 1). Some molecules (5, 6, 7, 8
and 11) displayed high autofluorescence (data not shown),
thereby possibly interfering with the excitation or emission
spectra of the fluorescent ligand Propranolol-green. Hence, we
repeated the heterologous binding competition assay using the
B2AR antagonist radioligand [3H]DHA to validate the results
obtained in the fluorescence binding assay. First, we charac-
terized the binding properties of the radioligand [3H]DHA in a
saturation binding experiment with increasing concentrations
of [3H]DHA and 5 μg SNAP-B2AR HEK membranes. The specific
binding curve (Figure S1) is saturable and with high affinity
with an equilibrium dissociation constant (KD) of 0.3�0.1 nM
(mean�SD, n=3). In the heterologous binding competition
assay compound 1 (MS008) and isoproterenol were used as
reference molecules and the determined pKi values of 7.1�0.1
for 1 (MS008) and 7.0�0.1 for isoproterenol were consistent
with the values obtained in the fluorescent ligand binding assay
(pKi of 7.0�0.1 for 1 (MS008) and 6.6�0.1 for isoproterenol).
As can be seen in Figure 2B and Table 2, the pKi values obtained
in the radioligand binding assay for compounds 5, 6, 7, 8 and
11 were comparable to the values determined in the
fluorescent ligand binding assay.
As the next step, a cAMP inhibition assay was performed in
order to test for the antagonistic properties of the 12 NCEs
identified here on the B2AR. The decrease of cAMP concen-
tration upon addition of 1 (MS008) confirms that it acts as an
antagonist (Figure 3A). To determine a pIC50 value of the novel
B2AR antagonist 1 (MS008), the concentration-response curve
was plotted (Figure 3B) and the data fitted using nonlinear
regression. To compare the potencies of the new B2AR
antagonists (2–12), the cAMP inhibition assay was performed
and pIC50 values were compared (Figure 4). The well-known
B2AR antagonist ICI 188551 served as a reference and displayed
a pIC50 of 8.8�0.1 (mean�SD, n=3). The novel compounds are
less potent than this molecule (pIC50 values ranging from 4.4 to
Figure 2. A) Heterologous HTRF competition binding experiments with Propranolol-green on SNAP-B2AR HEK membranes. Heterologous competition binding
experiments were performed on SNAP-B2AR HEK membranes in the presence of 50 nM Propranolol-green and NCEs at the concentrations indicated.
Nonspecific binding was determined in the presence of 10 μM ICI 118551. Specific binding in the absence of NCEs was set to 100%. Isoproterenol was used as
reference compound. Data represent the mean�SD from three to five independent experiments carried out in duplicate. B) Heterologous radioligand
competition binding experiments with [3H]DHA on SNAP-B2AR HEK membranes. The binding reaction was carried out in 200 μL containing membranes (5 μg
of protein), WGA PVT SPA beads (500 μg), [3H]DHA (final concentration 1 nM), and increasing concentrations of NCEs for 120 min. Nonspecific binding was
determined in the presence of 1 μM ICI 118551. Specific binding in the absence of NCEs was set to 100%. Data represent the mean�SD from three
independent experiments carried out in duplicate.
Table 2. Heterologous competition radioligand binding assay of selected
compounds from the analogue search to the B2AR (with [3H]DHA). pKi
values were determined in an equilibrium competition binding assay with
1 nM [3H]DHA. pKi is defined as -logKi and values are shown as mean�SD
of at least three independent experiments carried out in duplicate. 1
(MS008) was used as reference compound.
Compound pKi n
1 (MS008) 7.1�0.1 3
5 5.5�0.1 4
6 6.1�0.1 3
7 6.0�0.1 3
8 6.7�0.1 3
11 6.3�0.1 3
Isoproterenol 7.0�0.1 3
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5.1, see Figure 4, Table 3). A similar cAMP inhibition assay was
repeated with cells overexpressing the B1AR to confirm that the
molecules act on this receptor in the same way as on the B2AR
(Figure S2 and Table S2).
Overall hit rate
In the primary screen only 1 of 27 molecules showed an
unambiguously determinable affinity for the B2AR (hit rate
3.7%). This low hit rate might be caused by the focus on novel
ligand scaffolds which is also manifest when comparing the
compounds tested in 2009[6] as well as the compounds tested
here against their respective ChEMBL datasets (see the Support-
ing Information). All 11 molecules from the similarity search
based on 1 (MS008) displayed a measurable affinity at the B2AR
(hit rate 100%). In summary, this results in an overall hit rate of
12 ligands out of 38 tested molecules (32%).
Comparison with our previous docking to the
carazolol-bound B2AR structure
It is a constant question whether the information inherent in
novel X-ray structures of the same receptor would call for the
repetition of a screening campaign, even in cases where the
observed structural differences are small. The present study
allows us to assess the effects of potentially subtle changes by
comparing our findings to the results of an earlier virtual screen
we had conducted using the structure of the complex of the
B2AR with carazolol (2RH1).[6] Comparison of the two crystal
structures 3NY9 (used in the present study) and 2RH1 (used
in[6]) based on the RMSD shows that the differences are fairly
small with a backbone RMSD of only 0.388, an all-heavy-atom
Figure 3. A) Real-time traces of whole-cell cAMP inhibition of 1 (MS008) in SNAP-B2AR-EPAC HEK cells. SNAP-B2AR-EPAC HEK cells were stimulated with
500 nM isoproterenol for 10 min, followed by addition of 1 (MS008) at the concentrations indicated for an additional 40 min. The EPAC FRET ratio
(mCerulean/mCitrine) was plotted as a function of time. Data represent mean�SD of one representative out of five individual experiments carried out in
duplicate. B) Concentration-response curve of compound 1’s (MS008) cAMP inhibition in SNAP-B2AR-EPAC HEK cells. The EPAC FRET ratio (mCerulean/
mCitrine) was normalized to 500 nM isoproterenol without inhibition (=100%), and the area under the curve (AUC) was plotted as a function of the
concentrations of 1 (MS008). Data represent the mean�SD of one representative out of five individual experiments carried out in duplicate.
Figure 4. Inhibition of whole-cell cAMP in SNAP-B2AR-EPAC HEK cells by
NCEs. SNAP-B2AR-EPAC HEK cells were stimulated with 500 nM isoproterenol
for 10 min, followed by the addition of NCEs at the concentrations indicated
for an additional 40 min. The EPAC FRET ratio (mCerulean/mCitrine) was
normalized to 500 nM isoproterenol without inhibition (=100%), and the
area under the curve (AUC) was plotted as a function of NCE concentrations.
Data represent the mean�SD for three to five independent experiments
carried out in duplicate.
Table 3. cAMP B2AR inhibition assay. pIC50 values of cAMP inhibition assay
performed with the 12 novel B2AR ligands and ICI 118551 as a reference.
pIC50 is defined as -logIC50, and data represent mean�SD for three to five
independent experiments carried out in duplicate.
Compound ID pIC50 n
1 (MS008) 5.1�0.1 5
2 5.1�0.1 3
3 N.D. 2
4 4.7�0.1 3
5 N.D. 2
6 4.4�0.1 4
7 N.D. 2
8 4.6�0.1 3
9 N.D. 2
10 N.D. 2
11 4.5�0.2 5
12 N.D. 2
ICI 118551 8.8�0.1 3
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RMSD of 0.650 and a binding pocket (residues within 5 Å of
carazolol) RMSD of 0.357.
First, we evaluated whether the molecules chosen from the
current version of the ZINC database could have been
discovered from the database version used in the 2RH1 study.
We found that the ZINC7 database contained only two out of
the 27 molecules selected in the present study, at ranks 4611,
and 40882.
Conversely, would the six ligands identified in ref.[6] have
been found in the present docking calculation, that is, would
they have been ranked sufficiently well? The six molecules were
docked to crystal structure 3NY9 to answer this question, using
the same parameters as for the screen of the entire ZINC library.
The six compounds would have come in at ranks 345,
19519, 20332, 16928, 426387, 3048263, respectively (Table 4).
This means that only the highly potent compound 1[6] would
have been discovered in the present screen.
Discussion
SAR results
The structural similarity of the eleven molecules from the
similarity search to 1 (MS008) and the parent molecule allowed
us to evaluate the respective impact of these moieties on their
binding affinity to the B2AR (see also Table 1). Two main results
emerged, which we will discuss in more detail in the following.
First, the core structure of a coumaran with an attached primary
amine and an aromatic moiety displays high affinity toward the
B2AR. Second, the analysis of the respective pKi values and
docking poses of the twelve molecules suggests that an
interaction with T195 stabilizes the binding mode, thereby
resulting in an increased affinity for the B2AR as explained in
more detail below.
It has to be noted that the molecules from the similarity
search mostly differ in the substituents attached to the aromatic
moiety attached to the coumaran scaffold. These substituents
can be located in ortho, meta or para position relative to the
coumaran scaffold. In general, a methoxy or hydroxy group in
para position resulted in higher binding affinity to the B2AR for
our ligands. According to the docking poses, this might be
caused by an interaction of this substituent with residue T195
in ECL2 (1 (MS008), 2, 4, 6, 8; pKi=6.0–7.0). Exchanging the
hydroxy group in the para position for an amide group
surprisingly does not change the affinity by much (pKi(4)=6.2
vs. pKi(7)=5.9 and pKi(11)=6.1). Based on the docking pose,
the carbonyl oxygen interacts via a hydrogen bond with T195
and, therefore, forms the same stabilizing interaction as hydroxy
and methoxy groups. It would be interesting to investigate the
influence of a further elongation of the amide substituent,
maybe even targeting the exosite (at the top of the binding
pocket where salmeterol reaches).[23] This might constitute a
way to introduce selectivity against the B1AR by targeting this
more dissimilar region of the two receptors.
In general, the interaction of our NCEs with T195 seems to
have an important effect on affinity (e.g., 1 (MS008), 6, 11),
since a loss of binding affinity is observed in compounds that
lack this interaction (e.g., 5, 3). However, this lack of binding
affinity based on a lack of T195 interaction could be partially
compensated by, for example, an interaction with N2936.55,
resulting in lower binding affinities (with pKi values ranging
from 4.6–5.7) for, for example, 5 and 10 than the one observed
for the compound interacting with T195 (pKi 7.0 for 1 (MS008)).
Furthermore, a fluorine substituent in meta position seems
to have a positive effect on ligand binding affinity (pKi(4)=6.2
vs. pKi(8)=6.8). This positive effect is consistent with an
interaction of the slightly negatively polarized fluorine with the
slightly positively polarized α-carbon of A2005.39.[24] The addition
of a second fluorine in meta position does not affect the
binding affinity for the B2AR, however, which suggests that
another fluorine substituent in this position cannot interact
with a matching residue in the binding pocket (pKi(1 (MS008))
=7.0 vs. pKi(2)=6.9).
A fluorine substituent on the coumaran moiety does not
seem to have an influence on affinity. Yet, this substituent is
pointing towards S2035.42, S2045.43 and S2075.46 in helix V and
might be exchanged against, for example, a hydroxy group. As
these residues are deeply involved in receptor activation, an
interaction with one of them could potentially not only increase
binding affinity but also result in agonistic effects elicited by
such a compound (6).
Compound 12 shows the lowest affinity for the B2AR (pKi
(12)=4.6) which is probably caused by the bulkier substituents
attached to the aromatic moiety as well as less favorable
interactions of the hydroxy groups with the protein due to
unfavorable angles caused by the longer substituent chain.
Comparison with the previous docking to the
carazolol-bound B2AR structure
A comparison of the current docking study to the docking
performed with the carazolol-bound structure in 2009[6] leads us
to two observations. First, and entirely not surprising, commer-
cial libraries are growing and might feature new ligands even
for well-investigated targets. Our study emphasized that there
are still novel ligands for the B2AR to be discovered, despite
many years of drug research and design with this receptor.
Table 4. Comparison of docking results with [6]. The ranks for the six hits
and their enantiomers from the docking screen against the carazolol-
bound structure[6] were compared with their ranks in the docking setup as
used in this study. “Rank 2009” denotes the ranks of the respective
molecules in ref. [6], “Rank 2RH1” and “Rank 3NY9” are the ranks that these
molecules obtained within the database docked in the present study.
No. ZINC ID Rank 2009 Rank 2RH1 Rank 3NY9
1 C04008295 15 182 345
C04008294 19 1948 1804
2 C03003177 150 9560 19519
3 C02880812 163 9881 88007
C02880813 273 1456 20332
4 C06703239 409 16166 16928
5 C04123268 182 12790 426387
6 C20589273 – 1443595 3048263
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Second, with one exception, the ligands of each of the two
screens would not have been discovered from the respective
other screen. This strongly suggests that new receptor crystal
structures add diversity to the docking process, even if the
novel structures differ only slightly from previous structures.
Hence, exhausting the available structural information, repeat-
ing calculations upon the availability of new information, and/
or deliberately generating slightly different conformations of a
receptor through homology modelling[17] presents itself as a
powerful strategy to maximize ligand yields.
Conclusion
The goal of this study was to identify novel antagonists for the
B2AR based on docking calculations to two crystal structures of
the B2AR in an inactive conformation (PDB IDs: 3NY9 and
2RH1). A special focus was directed towards the discovery of
unprecedented ligand scaffolds for the B2AR.
Given the additional constraint imposed by the goal of
finding novel ligand scaffolds, we anticipated a rather low hit
rate, even for such a well-described target as the B2AR. Indeed,
the hit rate of 3.7% of the fluorescence-based first screen was
consistent with these expectations. However, the discovery of
the novel coumaran-based scaffold (2,3-dihydro-1-benzofuran-
2-ylmethanamine) shows that it is still possible to find ligands
with scaffolds unprecedented for the B2AR. Based on this novel
scaffold, we searched for analogues by a combination of
similarity- and structure-based methods and tested all of them
in a binding assay. This analogue search was very successful
with the entire set of eleven molecules showing affinity for the
B2AR. This not only shows that the coumaran-based scaffold
itself represents a highly adaptable basis for novel B2AR ligands,
but also demonstrates that docking effectively discriminated
ligands from non-binders.
Because all docking calculations were based on crystal
structures of the B2AR in an inactive conformation, it was
expected that the novel ligands would all act as antagonists, an
assumption that was confirmed by functional assays (Figure 4).
Furthermore, the results were compared with the ones of a
previous docking study.[6] This showed that, firstly, the ever-
growing libraries of small molecules available from various
vendors still contain ligands with novel scaffolds even in well-
explored regions of chemical space, and secondly, that new
receptor crystal structures add information to conformational
space, even if differences to previous structures seem to be
small.
Experimental Section
Docking. Two crystal structures in an inactive conformation (PDB
IDs 3NY9 and 2RH1) were prepared for docking by addition of
missing residues, protonation and minimization with CHARMm and
the CHARMm22 force field.[25] The ZINC12[26] lead-like subset
containing 3,687,621 molecules was then docked to both structures
using DOCK3.6.[27–31] Molecules were chosen based on the resulting
ranking lists by visual inspection of the molecule poses of the top
500 ranked molecules. Further diversity within the picked molecules
was achieved by a dual reranking of the dockings based on a
comparison of the ranking lists according to Equation 1 of ref. [32].
This way, compounds ranking favorably in both conformations
were prioritized. Furthermore, distance filters to several residues in
the ECL2 (within 2.6 Å of F19345.52 (backbone), D19245.51 (sidechain),
C19145.50 (backbone) and T195 (sidechain); individually and in
combination) were used for a specific search of molecules
interacting with ECL2 residues in their docking pose. The selected
molecules were grouped into “no ECL2 interaction”, “interaction
with T195” and “interaction with one of C19145.50-F19345.52”, to allow
further evaluations based on interactions with ECL2. Furthermore, a
variety of scaffolds was explored to allow the discovery of new
structural scaffolds binding to the B2AR aside from β-hydroxy-
amines. The interaction of the molecules with D1133.32 either by an
amine or an amide was essential for the selected molecules. Using
these criteria, a total of 27 molecules was selected to be purchased
(Table S5).
Analogue search by catalogue. To explore the SAR of 1 (MS008)
further, a Tanimoto search was performed on the ZINC15[33] lead-
like subset containing 5,626,190 molecules. The search was based
on ECFP4 fingerprints and a Tanimoto similarity cutoff of 0.5. To
avoid compatibility problems between ZINC15 and DOCK3.6, the
molecules were retrieved from ZINC12. The resulting set of
molecules was docked to the structure 3NY9 using DOCK3.6 and
molecule poses were visually inspected (see Table S1 for SMILES of
selected compounds).
Calculation of RMSDs between crystal structures. In order to
quantify the structural similarity between the two crystal structures
used in the docking calculations, 2RH1 and 3NY9, RMSDs were
calculated. The structures were used as prepared for the docking
calculations (without hydrogen atoms) and adapted to have the
same number of residues. They were then aligned in witnotp
(Novartis Pharma AG, unpublished) and RMSDs calculated with this
program. RMSDs were calculated for all backbone heavy atoms
(1112 atoms) and for all heavy atoms including the side chains
(2239 atoms). Furthermore, the RMSD value for all heavy atoms of
the residues in 5 Å proximity to the crystallized ligand in 2RH1 was
calculated.
Cell lines. A HEK293 cell line stably expressing the SNAP-β2-
adrenergic receptor (referred to as SNAP-B2AR) was purchased
from Cisbio (Codolet, France). The SNAP-B2AR cell line in a HEK293
background stably expressing the EPAC-cAMP sensor with mCer-
ulean and mCitrine as FRET pair, further referred to as SNAP-B2AR-
EPAC, was generated by transfecting a SNAP-B2AR plasmid into a
cell line stably expressing the EPAC-cAMP sensor[34] using Lipofect-
amine 2000. SNAP-B2AR-EPAC clones were selected by cultivating
the cells in DMEM containing 10% FCS, 2 mg/ml G418 and
0.06 mg/ml zeocin in a humidified 5% CO2 air incubator at 37 °C.
Membrane preparation. For the HTRF binding assay, SNAP-B2AR
cells were labeled with 100 nM SNAP-Lumi4®-Tb in HBSS buffer
(supplemented with 20 mM HEPES, pH 7.4) for 1 h at 37 °C, 5%
CO2. For the radioligand binding assay, unlabeled SNAP-B2AR cells
were used for the membrane preparation. SNAP-B2AR cells were
grown to confluency in T175 culture flasks, washed once with ice-
cold phosphate-buffered saline (PBS) and scraped off the tissue
culture plate in ice-cold PBS. After centrifugation at 1200 g for
7.5 min (4 °C), the cell pellet was resuspended in ice-cold HME
buffer (20 mM HEPES, 2 mM MgCl2, 1 mM EDTA, pH 7.4) and
subjected to one freeze/thaw cycle with liquid nitrogen. The
thawed samples were then further homogenized by sonication
using a Branson Sonifier Cell Disruptor B15 (output control=3;
duty cycle=30%; pulsed mode) with 10×5 pulses and membranes
were sedimented by centrifugation for 30 min at 20 000 g (4 °C).
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The supernatant was discarded and cell pellets were resuspended
in ice-cold HME buffer. Membrane emulsions were further homo-
genized by passing the emulsions several times through a syringe
with a diameter of approx. 0.6 μm. The total protein concentration
of the membrane preparations was determined with a Pierce BCA
Protein Assay Kit (ThermoFisher Scientific) according to the
manufacturer’s protocol. Membrane samples of 5–10 g/ml were
aliquoted, frozen in liquid nitrogen and stored at   80 °C.
Heterologous competition HTRF binding assay. Equilibrium bind-
ing with NCEs was carried out in a final volume of 30 μL containing
2 μg membrane proteins, 50 nM Propranolol-green and the unla-
beled NCEs at the concentrations indicated in binding buffer (HBSS
buffer supplemented with 20 mM HEPES) in 96-well PCR plates.
Nonspecific binding of 50 nM Propranolol-green was measured in
the presence of 10 μM ICI 118551. The binding reaction was carried
out for 120 min at RT under gentle agitation. 25 μL of the incubated
reaction mixtures were transferred to white, opaque 384-well plates
for measuring. The FRET signal between SNAP-Lumi4®-Tb (620 nm;
donor) and Propranolol-green (520 nm; acceptor) was measured
using a PHERAstar FSX from BMG Labtech (Ortenberg, Germany)
and a dual emission optic module (337/620/520) for time resolved
fluorescence. Samples were excited at 337 nm using 30 laser flashes
per well and emission was detected at 520 nm and 620 nm
respectively. Signal integration for both emission wavelengths was
delayed by 60 μs and lasted for 400 μs. For the competition binding
curves of the unlabeled NCEs, the nonspecific binding was
subtracted from the total binding to obtain specific binding values.
Binding curves were normalized to the maximal response of specific
binding. To calculate the Ki values the data was fitted by using
nonlinear regression in GraphPad Prism 8.
Heterologous competition radioligand binding assay. Equilibrium
binding with NCEs was carried out in a final volume of 200 μL
containing 5 μg membrane proteins, 500 μg WGA PVT SPA beads,
1 nM [3H]DHA and the unlabeled NCEs at the concentrations
indicated in binding buffer (HBSS supplemented with 2 mM HEPES,
0.1% (w/v) BSA)). Nonspecific binding of 1 nM [3H]DHA was
measured in the presence of 1 μM ICI 118551. The binding reaction
was carried out for 120 min at RT under gentle agitation and
terminated by 10 min centrifugation at 453 g at RT for 10 min.
Radioactivity was quantified using single photon counting on a
TopCount NXT microplate scintillation and luminescence counter
(Packard). In all experiments, total binding did not exceed 10% of
1 nM [3H]DHA and we assume that the free concentration of [3H]
DHA is approximately equal to the added concentration at every
time point. For competition binding curves of the unlabeled NCEs,
the nonspecific binding was subtracted from the total binding to
obtain specific binding values. Binding curves were normalized to
the maximal response of specific binding. To calculate the Ki values
the data was fitted using nonlinear regression in GraphPad Prism.
Real-time cAMP inhibition assays. To be able to measure the
accumulation and degradation of cAMP upon stimulation or
inhibition of the B2AR, a cAMP assay was performed as previously
described.[35,36] SNAP-B2AR-EPAC cells were seeded at a density of
50’000 cells/well in sterile, black 96-well microplates coated with
poly-l-lysine and cultured overnight. Cells were incubated in 80 μL
HBSS (supplemented with 20 mM HEPES, pH 7.4) in darkness for
15 min prior to stimulation with ligands at the concentrations
indicated at RT. Increases in the mCerulean/mCitrine ratio reflecting
increasing cAMP levels were measured using a PHERAstar FSX from
BMG Labtech (Ortenberg, Germany) upon excitation with 10 flashes
(flash lamp) per well at 430 nm. Excitation of the EPAC donor
(mCerulean) and emission of EPAC donor and the EPAC acceptor
(mCitrine) was performed with a dual emission fluorescence optical
module (FI 430 530 480). mCerulean/mCitrine ratios were plotted as
a function of time for 40 min post stimulation. IC50 values were
calculated from concentration-response curves with area under the
curve (AUC) vs. ligand concentrations plotted in GraphPad Prism 8.
Data analysis. For the competition binding experiments the specific
binding values were fitted using the nonlinear regression “One site
– Fit Ki” in GraphPad Prism 8 to calculate the Ki. For the saturation
binding curves the total and nonspecific as well as specific binding
were fitted with the “one site total and nonspecific binding” and
“one site specific binding” fitting model, respectively, in GraphPad
Prism. The KD of the labeled ligands (Propranolol-green or [
3H]DHA)
was obtained from the fit of the specific binding curve. For the
cAMP inhibition assay the concentration-response curves with area
under the curve (AUC) vs. ligand concentrations were fitted using
the nonlinear regression “log(inhibitor) vs. response (three parame-
ters)” in GraphPad Prism to calculate the IC50 values.
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